Carregando empresa
Just reported
Q3 FY2027 results
From Kenvue's results release of 30 de outubro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 3,89B
+3,2% y/y
-1,7% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 0,22
+4,8% y/y
-8,3% q/qGuided
—
No guide given
Operating income, GAAP
Actual
US$ 706M
+12% y/y
+1,0% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Kenvue is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Household and Personal Products
Graded A or B and worth $2B or more: A first, then the largest.
PGProcter & Gamble CoUS$ 393,6BA+
CLColgate-Palmolive CompanyUS$ 79,2BA
ELFe.l.f. Beauty, Inc.US$ 7BA
ELEstee Lauder Companies IncUS$ 40,5BB
IPARInterparfums, Inc.US$ 4,3BB+
Grade rose recently in Consumer Staples
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
BUDAnheuser-Busch InBev SA30 de jul. de 2026BAGraded B, now A
MDLZMondelez International, Inc.29 de out. de 2026CAGraded C, now A
HSYHershey Co.29 de out. de 2026BAGraded B, now A
SYYSysco Corporation4 de nov. de 2026BAGraded B, now A- ELFe.l.f. Beauty, Inc.4 de nov. de 2026BAGraded B, now A
Como ganha dinheiro
- Self Care43%
- Essential Health31%
- Skin Health and Beauty27%
As participações na receita são estimativas para quarter ended 2026-09-27, não números de um relatório oficial.
Concorre com
O que vende6
Tylenol
Nonprescription medicines for pain and fever.
Zyrtec
Medicines for allergy symptoms.
Nicorette
Products to help people stop smoking.
Mostrar mais 3
Neutrogena
Skin and hair care products, including face and body care.
Listerine
Mouthwash and other oral care products.
BAND-AID Brand
Adhesive bandages and other wound-care products.
Quem compra3
- Retailers and pharmacies buy branded products for resale in stores and through their online shops.
- Online retailers sell Kenvue products to consumers through e-commerce channels.
- Consumers buy the products through retail, pharmacy and online channels.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1Kenvue relies on outside manufacturers for some products and on third-party operators for most of its distribution centers.
- 2It buys most raw and packaging materials from outside suppliers; some materials come from a single supplier or a limited number of suppliers, and commodity prices can change.
- 3Some legacy Johnson & Johnson names and branding, including Johnson’s, are used under licenses with varying durations.
O que pode dar errado
- 1The pending combination with Kimberly-Clark depends on remaining regulatory approvals and other closing conditions; delay or failure to complete it could disrupt operations, customers, suppliers or employees.
- 2Product safety, ingredient or labeling concerns can lead to recalls, regulatory action, lawsuits and reputational harm; Kenvue also faces talc-related proceedings involving Johnson’s Baby Powder sold outside the United States and Canada.
- 3Competition from other brands and retailer-owned products, changing consumer preferences, and retailers’ ordering and inventory decisions can affect sales; Kenvue has also faced distribution losses in some product categories.
Demonstrações financeiras completas →
Sobre a Kenvue Inc.
Its brands include Tylenol and Zyrtec medicines, Neutrogena skin and hair care, Listerine mouthwash, and BAND-AID wound-care products. It sells through retail and online channels around the world. Kenvue has a pending agreement to combine with Kimberly-Clark, subject to remaining conditions and regulatory approvals.
- Sede
- Summit, New Jersey, United States
- Fundada em
- 2022
- Funcionários
- approximately 22,000 (as of December 28, 2025, high)
- Listada em
- NYSE
- Fim do exercício
- December
Construído a partir dos próprios documentos de Kenvue Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
